Sino Biopharm has disclosed encouraging initial human data for its PD-1xVEGF bispecific antibody, MK-2010, revealing that six out of eleven lung cancer patients exhibited a positive response to a low dosage of the treatment. Additionally, four of nine patients in a separate cohort also showed favorable outcomes, underscoring the potential of this therapeutic approach in a challenging oncology landscape.
This data emerges at a time when bispecific antibodies are gaining traction as innovative solutions in cancer therapy, offering dual-targeting mechanisms that may enhance efficacy. The implications of these findings could be significant, particularly for Merck, which is collaborating with Sino Biopharm, as they navigate the competitive landscape of immuno-oncology.
In a related development, Biogen has committed $100 million to secure rights for an antibody, signaling a robust investment in its pipeline. This acquisition reflects Biogen’s strategic focus on expanding its therapeutic portfolio, particularly in the realm of biologics, where demand continues to escalate.
Start your 7-day trial and see what the database can do →
